¹²³I-Radiopharmaceutical

Iodine-123, a gamma-emitting radioisotope with a 13.2-hour half-life, is an essential tool in nuclear medicine due to its chemical versatility, high-resolution imaging capabilities, and minimal radiation exposure. At Alfa Cytology, we specialize in preclinical development services for ¹²³I-labeled radiopharmaceuticals.

Overview of ¹²³I-Based Radiopharmaceuticals

Iodine-123 possesses unique characteristics that make it a cornerstone of radiopharmaceutical research. With a short half-life of 13.2 hours, it provides sufficient time for imaging while minimizing long-term radiation exposure. Its emission of 159 keV gamma rays is ideal for high-resolution SPECT imaging, and its chemical versatility allows seamless integration into organic molecules, enabling diverse applications in molecular imaging.

Fig.1. [¹²³I]CC1 was synthesized from precursor 9 via a copper-mediated iododeboronation reaction. (Chung Ying Chan, et al., 2023)

Our Services

At Alfa Cytology, we excel in providing ¹²³I-labeled radiopharmaceutical, imaging agent, and tracer development services designed to meet the needs of diverse biological targets. Whether for oncology, neurology, cardiology, or other applications, we provide specific solutions starting from early design to preclinical evaluation.

Target Discovery Services for ¹²³I-Radiopharmaceutical Development

At Alfa Cytology, we specialize in providing cutting-edge ¹²³I radiopharmaceutical services tailored to diverse biological targets. Our expertise supports research and development across a range of disease areas, ensuring high-quality solutions for your imaging and drug development needs.

¹²³I-Radiopharmaceutical Development

¹²³I Radiolabeling Design and Synthesis Services

Leveraging the ideal half-life and energy profile of ¹²³I, we design and synthesize efficient ¹²³I-labeled compounds. We focus on optimizing the stability of radiolabeling, and ligand binding efficiency.

• Radionuclide-Antibody Conjugation
• Radionuclide-Small Molecule Conjugation

• Radionuclide-Peptide Conjugation
• Radionuclide-siRNA Conjugation

Radiolabeling and Quality Control Services

Our ¹²³I radiolabeling services are designed to ensure the highest standards of purity and stability. We utilize advanced techniques such as high-performance liquid chromatography (HPLC) and radio-thin layer chromatography (radio-TLC) to assess radiochemical purity, stability, and chemical integrity. With strict quality control protocols, we guarantee that the radiopharmaceuticals meet industry standards for both research and clinical applications.

In Vitro/In Vivo Efficacy Evaluation Services

We offer a comprehensive range of efficacy testing, including in vitro binding studies, cellular uptake assays, and in vivo biodistribution studies using animal models. Our SPECT imaging platform allows real-time visualization of tracer distribution, providing detailed insights into pharmacokinetics, target engagement, and therapeutic potential. This data is critical for assessing the safety and efficacy of ¹²³I-labeled compounds in preclinical studies.

Applications of ¹²³I-Based Radiopharmaceuticals

The versatility of ¹²³I continues to drive innovations in molecular imaging and diagnostics. Its proven success in preclinical studies supports the development of tracers for oncology, neurology, cardiology, and beyond.

For more information about our ¹²³I-radiopharmaceutical development services or to discuss your project, please contact us.

Reference

1. Chung Ying Chan, et al. (2023). [¹²³I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer. Journal of Nuclear Medicine. jnumed.123.265429.

• ⁶⁸Ga-Radiopharmaceutical
• ¹⁸F-Radiopharmaceutical
• ⁸⁹Zr-Radiopharmaceutical
• ⁹⁹mTc-Radiopharmaceutical
• ¹²⁵I-Radiopharmaceutical
• ¹³¹I-Radiopharmaceutical
• ¹¹C-Radiopharmaceutical
• ¹⁴C-Radiopharmaceutical
• ¹⁷⁷Lu-Radiopharmaceutical
• ⁹⁰Y-Radiopharmaceutical
• ⁸⁹Sr-Radiopharmaceutical
• ²²⁵Ac-Radiopharmaceutical